Jean Francois Formela is Director at Intellia Therapeutics, Inc. (NTLA). They have made 26 open-market trades across 8 companies since 2006, most recently 2026-09-14.
CIK 0001030575
6 open-market purchases totalling $17.3M since 2006, against 20 sales. Across 5 scored buys the stock is down 12.5% at ninety days, and 11.1 points behind the S&P over the same stretch.
5 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 40% | 60% | 60% |
| Avg Move | -7.1% | -6.9% | -12.5% |
| Alpha | -4.2% | -7.5% | -11.1% |
| Scored | 5 | 5 | 5 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| KRRO | SELL · 10b5-1 | 2026-09-11 | 2026-09-15 | $14.09 | $686K | -32.1% | -33.8% | — |
| KRRO | SELL · 10b5-1 | 2026-08-26 | 2026-08-28 | $13.96 | $4K | +4.9% | -23.7% | — |
| KRRO | SELL · 10b5-1 | 2026-08-19 | 2026-08-21 | $14.00 | $399K | -5.4% | -21.4% | — |
| KRRO | SELL · 10b5-1 | 2026-08-11 | 2026-08-13 | $13.96 | $30K | +5.1% | +7.2% | — |
| KRRO | SELL · 10b5-1 | 2026-07-02 | 2026-07-07 | $14.02 | $1.5M | -17.3% | -17.9% | -32.5% |
| KRRO | SELL · 10b5-1 | 2026-06-22 | 2026-06-24 | $14.34 | $2.5M | +7.0% | -21.8% | -23.8% |
| KRRO | SELL · 10b5-1 | 2026-05-28 | 2026-06-01 | $13.95 | $40K | -11.3% | +14.1% | +3.4% |
| IKNA | SELL | 2021-12-10 | 2021-12-14 | $14.76 | $688K | +1.1% | -22.2% | -60.3% |
| TBIO | SELL | 2021-09-14 | 2021-09-14 | $38.00 | $78.1M | -15.6% | -18.7% | -50.0% |
| NTLA | SELL | 2021-06-28 | 2021-06-29 | $132.73 | $146.9M | -4.4% | -11.5% | -4.7% |
| NTLA | SELL | 2021-06-11 | 2021-06-15 | $87.04 | $35.1M | +0.6% | +56.4% | +74.8% |
| NTLA | SELL | 2021-04-29 | 2021-04-30 | $85.43 | $771K | -17.3% | -4.8% | +77.0% |
| NTLA | SELL | 2021-04-26 | 2021-04-28 | $85.96 | $59.0M | -28.7% | -12.4% | +54.7% |
| NTLA | SELL | 2021-04-05 | 2021-04-07 | $84.98 | $68K | -7.0% | -6.4% | +106.5% |
| IKNA | BUY | 2021-03-30 | 2021-12-14 | $16.00 | $2.0M | +1.1% | -22.2% | -60.3% |
| NTLA | SELL | 2021-02-26 | 2021-03-01 | $60.29 | $60.5M | +3.9% | +26.4% | +16.1% |
| TBIO | SELL | 2020-12-21 | 2020-12-23 | $25.17 | $5.5M | -0.1% | -7.5% | -7.5% |
| TBIO | SELL | 2020-08-25 | 2020-08-27 | $14.79 | $2.1M | -0.1% | -7.5% | -7.5% |
| NTLA | SELL | 2018-07-16 | 2018-07-18 | $31.08 | $372K | -17.3% | -10.6% | -21.4% |
| NTLA | SELL | 2018-06-19 | 2018-06-20 | $27.90 | $334K | -6.8% | +2.6% | +3.8% |
| NTLA | SELL | 2018-05-16 | 2018-05-17 | $25.04 | $335K | +2.7% | +11.3% | +3.8% |
| NTLA | SELL | 2018-03-20 | 2018-03-22 | $23.87 | $1.9M | -4.0% | -11.5% | +33.9% |
| SPRO | BUY | 2017-11-06 | 2017-11-07 | $14.00 | $6.0M | +15.7% | -16.1% | -5.8% |
| NTLA | SELL | 2017-07-11 | 2017-07-11 | $16.07 | $1.3M | +1.2% | -0.2% | +79.3% |
| NTLA | SELL | 2017-07-10 | 2017-07-11 | $16.17 | $647K | +1.2% | -0.2% | +79.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.
| EGLT | 2,110,555 | $691K |
| TBIO | 46,640 | $151K |
| NTLA | 7,291 | $83K |
| SGXP | 2,485,068 | — |
| Total | $529.2M |
Shares reported on the most recent Form 4, priced at the 2026-09-15 close. 1 holding could not be priced and is excluded from the total.